- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02048371
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
Although regorafenib was approved for use in patients who had progressive GIST despite imatinib and/or sunitinib on the basis of phase II and phase III data, it has not been examined in a systematic fashion in patients with other forms of sarcoma.
Given the activity of sorafenib, sunitinib and pazopanib in soft tissue sarcomas, and evidence of activity of sorafenib in osteogenic sarcoma and possibly Ewing/Ewing-like sarcoma, there is precedent to examine SMOKIs (small molecule oral kinase inhibitors) such as regorafenib in sarcomas other than GIST. It is also recognized that SMOKIs (small molecule oral kinase inhibitors)such as regorafenib, sorafenib, pazopanib, and sunitinib have overlapping panels of kinases that are inhibited simultaneously. While not equivalent, most of these SMOKIs (small molecule oral kinase inhibitors) block vascular endothelial growth factor and platelet derived growth factors receptors (VEGFRs and PDGFRs), speaking to a common mechanism of action of several of these agents.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Although regorafenib was approved for use in patients who had progressive GIST despite imatinib and/or sunitinib on the basis of phase II and phase III data, it has not been examined in a systematic fashion in patients with other forms of sarcoma.
Given the activity of sorafenib, sunitinib and pazopanib in soft tissue sarcomas, and evidence of activity of sorafenib in osteogenic sarcoma and possibly Ewing/Ewing-like sarcoma, there is precedent to examine SMOKIs (small molecule oral kinase inhibitors) such as regorafenib in sarcomas other than GIST. It is also recognized that SMOKIs (small molecule oral kinase inhibitors)such as regorafenib, sorafenib, pazopanib, and sunitinib have overlapping panels of kinases that are inhibited simultaneously. While not equivalent, most of these SMOKIs (small molecule oral kinase inhibitors) block vascular endothelial growth factor and platelet derived growth factors receptors (VEGFRs and PDGFRs), speaking to a common mechanism of action of several of these agents
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Duarte, California, United States, 91010
- City of Hope National Medical Center
-
Los Angeles, California, United States, 90027
- Children's Hospital Los Angeles
-
Santa Monica, California, United States, 90403
- Sarcoma Oncology Research Center
-
Stanford, California, United States, 94305
- Stanford University
-
-
Florida
-
Jacksonville, Florida, United States, 32224
- Mayo Clinic - Florida
-
Tampa, Florida, United States, 33612
- H. Lee Moffitt
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana Farber/Partners Cancer Care
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic - Minnesota
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28203
- Carolinas HealthCare System
-
Durham, North Carolina, United States, 27705
- Duke University
-
-
Ohio
-
Columbus, Ohio, United States, 43202
- Ohio State University
-
-
Oregon
-
Portland, Oregon, United States, 97239
- Oregon Health and Science University
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University
-
-
Texas
-
Houston, Texas, United States, 77030
- Texas Children's Hospital
-
-
Utah
-
Salt Lake City, Utah, United States, 84112
- Huntsman Cancer Institute
-
-
Washington
-
Seattle, Washington, United States, 98109
- Seattle Cancer Care Alliance
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 10 year for Liposarcoma, Osteosarcoma, Ewing sarcoma and Mesenchymal Chondrosarcoma; Age ≥ 5 years for Rhabdomyosarcoma cohorts
- Weight ≥ 15 kg (33 lb)
- Patients must have histologically or cytologically confirmed advanced/metastatic liposarcoma, osteogenic sarcoma, Ewing/Ewing-like sarcoma of soft tissue or bone, fusion-positive alveolar rhabdomyosarcoma or embryonal rhabdomyosarcoma/fusion-negative alveolar rhabdomyosarcoma , or mesenchymal chondrosarcoma
- WHO Performance Status 0, 1 or 2. A maximum of 1/3 of patients in cohorts A & B may be WHO performance status 2
- At least one prior line of systemic therapy for the sarcoma diagnosis (neoadjuvant, adjuvant or metastatic disease)
- All acute toxic effects of any prior treatment have resolved to NCI-CTCAE v 4.0 Grade 1 or less (except alopecia) at the time of signing the Informed Consent Form (ICF)
- Subject must be able to swallow and retain oral medication
- At least one site of measurable disease on x-ray/CT/MRI scan as defined by RECIST 1.1
- Adequate organ function within 14 days of registration
- Written, voluntary informed consent
- Fertile men and women of childbearing potential must agree to use an effective method of birth control from Day 1 of study and for 3 months after last study drug administration in both sexes, as assessed by the investigator. Women of childbearing potential include pre-menopausal women and women within the first 2 years of the onset of menopause. Women of childbearing potential must have a negative pregnancy test less than or equal to seven days prior to Day 1 of study. The definition of adequate contraception will be based on the judgement of the investigator.
- Evidence of progression of disease as defined by RECIST 1.1 (i.e. new disease sites or 20% growth of index lesions) within 6 months of registration
- Patients with central nervous system disease are eligible for enrollment if they have received prior radiotherapy or surgery to sites of CNS (central nervous system) metastatic disease and are without evidence of clinical progression for at least 12 weeks after therapy
Exclusion Criteria:
- Patients with documentation of well differentiated liposarcoma only (of the well differentiated/dedifferentiated liposarcoma family) are specifically excluded, owing to its characteristically slow growth. If high grade areas are suspected (dedifferentiation), but not proved by pathology analysis (e.g. after primary resection of a well-differentiated liposarcoma), a biopsy must be performed to demonstrate the high-grade dedifferentiated disease
- Prior systemic therapy with a small molecule oral kinase inhibitor, including but not limited to: pazopanib, sunitinib, sorafenib, everolimus, sirolimus, vemurafenib, dasatinib and trametinib
- Previous assignment to treatment during this study. Subjects permanently withdrawn from study participation will not be allowed to re-enter study. Patients who progress on placebo are specifically allowed to enroll on the treatment arm of the study if they meet all other entry criteria
- Concurrent, clinically significant, active malignancies within 12 months of study enrollment
- Patients with severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol
- Major surgery within 28 days prior to study registration or those patients who have not recovered adequately from prior surgery
- Patients who have received wide field radiotherapy ≤ 28 days (defined as > 50% of volume of pelvis bones or equivalent) or limited field radiation for palliation < 14 days prior to study registration or those patients who have not recovered adequately from side effects of such therapy
- Patients who have received prior systemic therapy < 14 days prior to study registration or have not recovered adequately from toxicities to CTCAE v. 4.03 grade 1 or less; prior investigational therapy may not have been given < 5 half-lives of last dose of treatment, or < 14 days, whichever is greater
- Patients who have had prior autologous, or allogeneic bone marrow transplant
- Uncontrolled hypertension (systolic pressure >140 mm Hg or diastolic pressure > 90 mm Hg [NCI-CTCAE v 4.0] on repeated measurement) despite optimal medical management
- Active or clinically significant cardiac disease including: Congestive heart failure-New York Heart Association (NYHA) > class II, Active coronary artery disease, Cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin, Unstable angina (anginal symptoms at rest), new onset angina within 3 months before randomization, or myocardial infarction within 6 months before randomization
- Evidence or history of bleeding diathesis
- Any hemorrhage or bleeding event ≥ NCI CTCAE Grade 3 within 4 weeks prior to study registration
- Subjects with thrombotic, embolic, venous, or arterial events, such as cerebrovascular accident (including transient ischemic attacks) deep vein thrombosis or pulmonary embolism within 6 months of start of study treatment
- Known history of human immunodeficiency virus (HIV) infection or current chronic or active hepatitis B or C infection requiring treatment with antiviral therapy.
- Ongoing infection > Grade 2 NCI-CTCAE v 4.03
- Presence of a non-healing wound, non-healing ulcer, or benign bone fracture (patients with stress insufficiency fractures e.g. from osteoporosis or pathological fracture from tumor are eligible for study)
- Patients with seizure disorder requiring medication
- Proteinuria > 100 mg/dl on urine analysis
- Interstitial lung disease with ongoing signs and symptoms at the time of informed consent
- Pleural effusion or ascites that causes respiratory compromise (≥ NCI-CTCAE version 4.03 Grade 2 dyspnea)
- History of organ allograft (including corneal transplant).
- Known or suspected allergy or hypersensitivity to regorafenib, or excipients of the formulations given during the course of this trial
- Any malabsorption condition.
- Women who are pregnant or breast-feeding.
- Any condition which, in the investigator's opinion, makes the subject unsuitable for trial participation
- Substance abuse, medical, psychological or social conditions that may interfere with the subject's participation in the study or evaluation of the study results
- Inability to comply with protocol required procedures
- Use of any herbal remedy (e.g. St. John wort [Hypericum perforatum])
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Cohort A: Liposarcoma
Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off Regorafenib |
Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
|
Placebo Comparator: Cohort A: Liposarcoma, Placebo
21 days on and 7 days off Placebo |
21 days on and 7 days off
|
Active Comparator: Cohort B: Osteosarcoma
Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off Regorafenib |
Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
|
Placebo Comparator: Cohort B: Osteosarcoma, placebo
21 days on and 7 days off Placebo |
21 days on and 7 days off
|
Active Comparator: Cohort C: Ewing sarcoma
Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off Regorafenib |
Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
|
Active Comparator: Cohort D: Rhabdomyosarcoma
Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off Regorafenib |
Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
|
Active Comparator: Cohort E: Mesenchymal Chondrosarcoma
Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off Regorafenib |
Adults: 160 mg daily; 21 days on and 7 days off Pediatrics: 82mg/m2 (rounding to the nearest 20mg) daily; 21 days on and 7 days off
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free Survival (PFS). Cohort A and Cohort B
Time Frame: up to 3 years
|
The progression-free survival is the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse.
Cohort A (liposarcoma) and Cohort B (osteosarcoma).
PFS will be evaluated according to RECIST (Response Evaluation Criteria In Solid Tumors) 1.1, where a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
|
up to 3 years
|
Progression-free Survival (PFS). Cohort C, Cohort D, and Cohort E
Time Frame: up to 16 weeks
|
The progression-free survival is the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse.
Cohort C (Ewing/Ewing-like sarcoma).
PFS will be evaluated according to RECIST (Response Evaluation Criteria In Solid Tumors) 1.1.
|
up to 16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Number of Participants With Reported CTCAE (Common Terminology Criteria for Adverse Events) Version 4.03 Adverse Events. All Cohorts.
Time Frame: up to 3 years
|
Common Toxicity Criteria, also referred to as the Common Terminology Criteria for Adverse Events (CTCAE), is a standardized classification of side effects used in assessing drugs for cancer therapy.
Cohorts A, B, C, and D.
|
up to 3 years
|
Overall Response Rate (ORR). All Cohorts.
Time Frame: up to 3 years
|
The overall response rate (ORR) is the percentage of patients whose cancer shrinks or disappears after treatment.
ORR will be evaluated according to RECIST (Response Evaluation Criteria In Solid Tumors) 1.1
|
up to 3 years
|
Progression-free Survival (PFS), Cohorts A and B, After Crossover.
Time Frame: up to 3 years
|
The progression-free survival is the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse.
|
up to 3 years
|
Response Rate (RR), Cohorts A and B, After Crossover.
Time Frame: up to 3 years
|
The response rate (RR) is the percentage of patients whose cancer shrinks or disappears after treatment.
|
up to 3 years
|
Time to Tumor Progression (TTP), Cohorts A and B, After Crossover.
Time Frame: up to 3 years
|
Time to tumor progression (TTP) is the length of time from the date of diagnosis or the start of treatment for a disease until the disease starts to get worse or spread to other parts of the body.
|
up to 3 years
|
Overall Survival (OS). Cohorts A and B, After Crossover.
Time Frame: up to 3 years
|
Overall survival (OS) is the length of time from either the date of diagnosis or the start of treatment for a disease, such as cancer, that patients diagnosed with the disease are still alive.
|
up to 3 years
|
Disease Specific Survival (DSS). Cohorts A and B, After Crossover.
Time Frame: up to 3 years
|
Disease-specific survival refers to the percentage of people in a study or treatment group who have not died from a specific disease in a defined period of time.
|
up to 3 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Robert Maki, MD, PhD, University of Pennsylvania
Publications and helpful links
General Publications
- Riedel RF, Ballman KV, Lu Y, Attia S, Loggers ET, Ganjoo KN, Livingston MB, Chow W, Wright J, Ward JH, Rushing D, Okuno SH, Reed DR, Liebner DA, Keedy VL, Mascarenhas L, Davis LE, Ryan C, Reinke DK, Maki RG. A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study. Oncologist. 2020 Nov;25(11):e1655-e1662. doi: 10.1634/theoncologist.2020-0679. Epub 2020 Aug 20.
- Hattinger CM, Patrizio MP, Magagnoli F, Luppi S, Serra M. An update on emerging drugs in osteosarcoma: towards tailored therapies? Expert Opin Emerg Drugs. 2019 Sep;24(3):153-171. doi: 10.1080/14728214.2019.1654455. Epub 2019 Aug 14.
- Davis LE, Bolejack V, Ryan CW, Ganjoo KN, Loggers ET, Chawla S, Agulnik M, Livingston MB, Reed D, Keedy V, Rushing D, Okuno S, Reinke DK, Riedel RF, Attia S, Mascarenhas L, Maki RG. Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. J Clin Oncol. 2019 Jun 1;37(16):1424-1431. doi: 10.1200/JCO.18.02374. Epub 2019 Apr 23.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SARC024
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Liposarcoma
-
Mario Negri Institute for Pharmacological ResearchFondazione IRCCS Istituto Nazionale dei Tumori, Milano; Humanitas Hospital,...RecruitingLiposarcoma, Myxoid | Liposarcoma, Dedifferentiated | Liposarcoma, Round CellItaly
-
GlaxoSmithKlineCompleted
-
Johnson & Johnson Pharmaceutical Research & Development...PharmaMarCompletedLiposarcoma,MyxoidFrance, United States, Germany
-
The Netherlands Cancer InstituteUnknownMyxoid Liposarcoma of Soft TissueNetherlands, United Kingdom, Norway, United States, Denmark
-
Memorial Sloan Kettering Cancer CenterRecruitingSarcoma | Soft Tissue Sarcoma | Sarcoma,Soft Tissue | Dedifferentiated Liposarcoma | Recurrent Dedifferentiated Liposarcoma | Metastatic Dedifferentiated Liposarcoma | Unresectable Dedifferentiated LiposarcomaUnited States
-
Maria Sklodowska-Curie National Research Institute...Active, not recruiting
-
The Netherlands Cancer InstituteM.D. Anderson Cancer Center; Mayo Clinic; Radboud University Medical Center; Aarhus... and other collaboratorsRecruitingMyxoid LiposarcomaNetherlands
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI); Daiichi Sankyo, Inc.Completed
-
Systems Medicine LLCUnknown
-
Sarcoma Alliance for Research through CollaborationEli Lilly and CompanyRecruitingAdvanced Dedifferentiated LiposarcomaUnited States
Clinical Trials on Regorafenib
-
Second Affiliated Hospital of Guangzhou Medical...Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Shenzhen... and other collaboratorsActive, not recruitingHepatocellular Carcinoma Non-resectableChina
-
Zhongda HospitalSun Yat-sen University; Jiangsu Cancer Institute & Hospital; Zhejiang University and other collaboratorsNot yet recruitingHepatocellular Carcinoma
-
Spanish Cooperative Group for the Treatment of...BayerCompletedColorectal Neoplasms | Metastatic DiseaseSpain
-
Rennes University HospitalRecruiting
-
Taipei Veterans General Hospital, TaiwanChang Gung Memorial Hospital; Koo Foundation Sun Yat-Sen Cancer CenterCompletedMetastatic Colorectal CancerTaiwan
-
Spanish Cooperative Group for the Treatment of...BayerCompletedStudy Comparing Different Dose Approaches of Induction Treatment of Regorafenib in MCRC (RE-ARRANGE)Metastatic Colorectal CancerSpain
-
Tianjin Medical University Cancer Institute and...Not yet recruitingAdvanced/Metastatic Colorectal CancerChina
-
Gustave Roussy, Cancer Campus, Grand ParisBayerRecruiting
-
Institute of Mother and Child, Warsaw, PolandMaria Sklodowska-Curie National Research Institute of OncologyRecruitingOsteosarcoma | Ewing Sarcoma of BonePoland
-
Massachusetts General HospitalBayerCompletedAcute Myeloid LeukemiaUnited States